We Give Shareholders a Voice

Immunomedics, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) to Gilead Sciences, Inc. ("Gilead") (NASDAQ: GILD). Under the terms of the deal, Gilead will acquire Immunomedics for $88.00 per share in cash. The Immunomedics merger investigation concerns whether the Board of Immunomedics has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

To receive more information, please fill out the form.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.